Comparison between Minimally Invasive Surgery and Conventional Open Surgery for Patients with Spinal Metastasis: A Prospective Propensity Score-Matched Study
Hansen-Algenstaedt N, Kwan M, Algenstaedt P, Chiu C, Viezens L, Chan T, Lee C, Wellbrock J, Chan C, Schaefer C
SPINE. 2017;42(10):789-797.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Latuske E, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J
ONCOTARGET. 2017;8(17):29187-29201.

Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Degwert N, Latuske E, Vohwinkel G, Stamm H, Klokow M, Bokemeyer C, Fiedler W, Wellbrock J
EUR J HAEMATOL. 2016;97(3):239-44.

Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone
Schroeder M, Viezens L, Wellbrock J, Fiedler W, Ruether W, Algenstaedt P, Hansen-Algenstaedt N, Schäfer C
J SURG ONCOL. 2016;113(5):515-21.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts
Kebenko M, Drenckhan A, Gros S, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki J, Bokemeyer C, Wellbrock J, Fiedler W
CELL SIGNAL. 2015;27(2):373-81.

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension
Wellbrock J, Harbaum L, Stamm H, Hennigs J, Schulz B, Klose H, Bokemeyer C, Fiedler W, Lüneburg N
LUNG. 2015.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules
Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W
NEURO-ONCOLOGY. 2014;86(1):46-52.

Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
Wellbrock J, Sheikhzadeh S, Oliveira Ferrer L, Stamm H, Hillebrand M, Keyser B, Klokow M, Vohwinkel G, Bonk V, Otto B, Streichert T, Balabanov S, Hagel C, Rybczynski M, Bentzien F, Bokemeyer C, Kodolitsch Y, Fiedler W
PLOS ONE. 2014;9(8):e104742.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
Oliveira Ferrer L, Wellbrock J, Bartsch U, Penas E, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G
MOL CANCER. 2013;12(1):144.

The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature.
Oliveira-Ferrer L, Wellbrock J, Balabanov M, Klockow M, Hauschild J, Bokemeyer C, Fiedler W, Ergun S, Schuch G
CANCER LETT. 2012;326(2):161-167.

CD146: a new partner for VEGFR2.
Wellbrock J, Fiedler W
BLOOD. 2012;120(11):2164-2165.

Primary tumor dependent inhibition of tumor growth, Angio-Genesis, and perfusion of secondary breast cancer in bone.
Schäfer C, Schröder M, Fuhrhop I, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2011;29(8):1251-1258.

Clinical experience with antiangiogenic therapy in leukemia.
Wellbrock J, Fiedler W
CURR CANCER DRUG TAR. 2011;11(9):1053-1068.

Microcirculation of secondary bone tumors in vivo: the impact of minor surgery at a distal site.
Schäfer C, Fuhrhop I, Schröder M, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2010;28(11):1515-1521.

Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Wellbrock J, Bokemeyer C, Fiedler W
J Oncol. 2010;2010:317068.

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A, Decker S, Wellbrock J, Horst A, Vohwinkel G, Schuch G, Bokemeyer C, Loges S, Fiedler W
INVEST NEW DRUG. 2009.

Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative.
Wellbrock J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brümmendorf T, Fiedler W, Loges S
BRIT J HAEMATOL. 2008;142(1):115-118.

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Loges S, Butzal M, Wellbrock J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld D, Schuch G, Fiedler W
BIOCHEM BIOPH RES CO. 2007;357(4):1016-1020.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr